<DOC>
	<DOCNO>NCT01600703</DOCNO>
	<brief_summary>Recent study animal human demonstrate hormone GLP-1 ( glucagon like peptide 1 ) reduces intestinal production lipoprotein particle . The investigator therefore hypothesise drug sitagliptin prevents breakdown GLP-1 reduce intestinal lipoprotein production human . The investigator unable speculate whether sitagliptin affect hepatic lipoprotein production lack data animal study vitro data . Sitagliptin already approve treatment type 2 diabetes .</brief_summary>
	<brief_title>Sitagliptin Regulation Intestinal Hepatic Lipoprotein Particle Hepatic Glucose Production Humans</brief_title>
	<detailed_description>Each subject study twice 4-6 week apart random order single blind study . In study A receive single dose sitagliptin 100mg od . In study B receive placebo . A nasoduodenal tube sit fluoroscopic guidance day prior study . On day study regular liquid formula ( Great shake plus ) infuse 4am tube maintain constant fed state . A pancreatic clamp ( octreotide replacement glucose , insulin growth hormone ) along saline/sitagliptin start 7am . From 9am iv bolus deuterated-glycerol ( d5-glycerol ) along regular infusion deuterated leucine ( L- [ 5,5,5-2H3 ] . Regular blood sample draw assess lipoprotein kinetics .</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>1 . Men woman , age 18 60 year 2 . Body mass index 20 kg/m2 27 kg/m2 3 . Hemoglobin 130g/L . 4 . Normal glucose tolerance response 75g , 2hr OGTT 1 . Subject history hepatitis/hepatic disease active within previous two year . 2 . Any significant active ( past 12 month ) disease gastrointestinal , pulmonary , neurological , renal ( Cr &gt; 1.5 mg/dL ) , genitourinary , hematological system , severe uncontrolled treated untreated hypertension ( sit diastolic BP &gt; 100 systolic &gt; 180 ) proliferative retinopathy 3 . History diabetes OGTT indicative diabetes impair glucose tolerance . 4 . Any history MI clinically significant , active , cardiovascular history include history arrhythmia 's conduction delay ECG , unstable angina , decompensated heart failure . 5 . Any laboratory value : AST &gt; 2x ULN ; ALT &gt; 2x ULN TSH &gt; 6 mU/l 6 . Current addiction alcohol substance abuse determine investigator . 7 . Mental incapacity , unwillingness language barrier preclude adequate understanding cooperation 8 . Taking prescription nonprescription medication time study 9 . Having donate blood three month prior three month post study procedures 10 . A pregnancy test perform 1 3 day prior study female subject . Those test positive pregnancy exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Intestinal lipoprotein</keyword>
	<keyword>Apolipoprotein B48 apolipoprotein B100</keyword>
	<keyword>Pancreatic clamp</keyword>
	<keyword>DPPIV inhibitor</keyword>
</DOC>